Allodynia in migraine: Clinical observation and role of prophylactic therapy

Clinical Journal of Pain

Volumn 29, Issue 7, 2013, Pages 577-582

  Misra, Usha K ^a   Kalita, Jayantee ^a   Bhoi, Sanjeev K ^a  

^a Institute of Medical Sciences   (India)

Author keywords

allodynia; amitriptyline; divalproate; migraine; prophylaxis; randomized controlled trial

Indexed keywords

AMITRIPTYLINE; IBUPROFEN; RIZATRIPTAN; VALPROATE SEMISODIUM;

ADOLESCENT; ADULT; ALLODYNIA; ARTICLE; CHILD; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; XEROSTOMIA;

ADOLESCENT; ADULT; AMITRIPTYLINE; ANALGESICS, NON-NARCOTIC; CHILD; COMORBIDITY; FEMALE; HUMANS; HYPERALGESIA; INDIA; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 84879886329     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31826b130f     Document Type: Article

References (41)

1. Stewart WF, Lipton RB, Liberman J. Variation in migraine prevalence by race. Neurology. 1996;47:52-59. (Pubitemid 26243858)
2. Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614-624. (Pubitemid 30261897)
3. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol. 2004;55:27-36. (Pubitemid 38067358)
4. Tfelt-Hansen P, Lous I, Olesen J. Prevalence and significance of muscle tenderness during common migraine attacks. Headache. 1981;21:49-54. (Pubitemid 11147089)
5. Drummond PD. Scalp tenderness and sensitivity to pain in migraine and tension headache. Headache. 1987;27:45-50. (Pubitemid 17149492)
6. Kalita J, Yadav RK, Misra UK. A comparison of migraine patients with and without allodynic symptoms. Clin J Pain. 2009;25:696-698.
7. Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry. 1960;23:23-32.
8. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19-26. (Pubitemid 38067357)
9. Lipton RB, Pan J. Is migraine a progressive brain disease? JAMA. 2004;291:493-494. (Pubitemid 38129755)
10. Ashkenazi A, Sholtzow M, Shaw JW, et al. Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia. 2007;27:111-117. (Pubitemid 46169435)
11. Creach C, Radat F, Laffitau M, et al. Cutaneous allodynia in transformed migraine with medication overuse. Cephalalgia. 2003;23:656-657.
12. Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine: implications for treatment. CNS Drugs. 2004;18:337-342. (Pubitemid 38621681)
13. Landy SH, McGinnis JE, McDonald SA. Clarification of developing and established clinical allodynia and pain-free outcomes. Headache. 2007;47:247-252.
14. Burstein R, Levy D, Jakubowski M. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev Neurol (Paris). 2005;161:658-660. (Pubitemid 40933999)
15. Silberstein SD. Preventive treatment of migraine. Trends Pharmacol Sci. 2006;27:410-415. (Pubitemid 44051566)
16. Ramadan NM. Current trends in migraine prophylaxis. Headache. 2007;47:S52-S57. (Pubitemid 46587635)
17. Peroutka SJ, Snyder SH. Regulation of serotonin 2 (5-HT2) receptors labeled with [3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther. 1980;215:582-587. (Pubitemid 11210362)
18. Cutrer FM, Limmroth V, Moskovitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalagia. 1997;17:93-100. (Pubitemid 27166262)
19. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24:9-160.
20. Bigal ME, Lipton RB, Reed M, et al. Prevalence and characteristics of allodynia in headache sufferers: results from the American Prevalence and Prevention Study. Neurology. 2008;70:1525-1533. (Pubitemid 351589506)
21. Gazerani P, Andersen OK, Arendt-Nielsen L. A human experimental capsaicin model for trigeminal sensitization. Gender-specific differences. Pain. 2005;118:155-163. (Pubitemid 41566594)
22. Knight YE, Goadsby PJ. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience. 2001;106:793-800. (Pubitemid 33000183)
23. Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology. 2004;63:848-852. (Pubitemid 39297646)
24. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;46:1334-1343. (Pubitemid 44556426)
25. Hasselbalch SG, Madsen K, Svarer C, et al. Reduced 5- HT(2A) receptor binding in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1830-1838.
26. Togsverd M, Werge TM, Tanko LB, et al. Association of a dopamine beta-hydroxylase gene variant with depression in elderly women possibly reflecting noradrenergic dysfunction. J Affect Disord. 2008;106:169-172. (Pubitemid 350309676)
27. Ashkenazi A, Young WB. The effects of greater occipital nerve block and trigger point injection on brush allodynia and pain in migraine. Headache. 2005;45:350-354. (Pubitemid 40530200)
28. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281-286.
29. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994;44: 647-651. (Pubitemid 24129990)
30. Couch JR. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011;51:33-51.
31. Couch JR, Hassanein RS. Migraine and depression: effect of amitriptyline prophylaxis. Trans Am Neurol Assoc. 1976;101: 234-237.
32. Couch JR, Ziegler DK, Hassanein RS. Evaluation of amitriptyline in migraine prophylaxis. Trans Am Neurol Assoc. 1974;99:94-98.
33. Ziegler DK, Hurwitz A, Hassanein RS, et al. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol. 1987;44:486-489. (Pubitemid 17061928)
34. Ziegler DK, Hurwitz A, Preskorn S, et al. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol. 1993;50:825-830. (Pubitemid 23229308)
35. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis: changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry. 1973;36: 684-690.
36. Members of the Task Force: Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur J Neurol. 2006;13:560-572. (Pubitemid 43873628)
37. Pringsheim T, Diksic M, Dobson C, et al. Selective decrease in serotonin synthesis rate in rat brainstem raphe nuclei following chronic administration of low doses of amitriptyline: an effect compatible with an antimigraine effect. Cephalalgia. 2003;23: 367-375. (Pubitemid 36688127)
38. Ayata C, Jin H, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59:652-661.
39. Richelson E. Antidepressants and brain neurochemistry. Mayo Clin Proc. 1990;65:1227-1236. (Pubitemid 20332186)
40. Taverna S, Mantegazza M, Franceschetti S, et al. Valproate selectively reduces the persistent fraction of Na+ current in neocortical neurons. Epilepsy Res. 1998;32:304-308. (Pubitemid 28419498)
41. Taverna S, Sancini G,MantegazzaM, et al. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther. 1999;288:960-968. (Pubitemid 29254132)